IntrinsiQ President Discusses "Clinical Pathways" at Cancer Center Business Summit

* Reuters is not responsible for the content in this press release.

Thu Oct 8, 2009 6:35am EDT

WALTHAM, Mass.--(Business Wire)--
IntrinsiQ president Jeff Forringer will join a panel of top oncologists
discussing best-practices for implementing clinical pathways at the 2009 Cancer
Center Business Summit, October 8-9 in Dallas. 

The panel - and the conference overall - will focus on how leading oncology
practices are staying ahead of today`s new economic realities while continuing
to advance their quality of care. Standardizing care processes and new
evidence-based medicine initiatives are improving quality and reimbursement in
oncology practices large and small, nationwide. 

Forringer will draw from IntrinsiQ`s unmatched oncology treatment data that
shows how clinical pathways are created and used in different cancer care
settings across the U.S. 

WHAT: "Clinical Pathways: What, Why and How" Panel 

WHO: Jeff Forringer, president of IntrinsiQ, LLC 

WHEN: Thursday, Oct. 8, 2009 from 10:45 a.m. - 12:15 p.m. CT 

WHERE: Adolphus Hotel, Dallas, Texas 

About IntrinsiQ

IntrinsiQ, LLC is the leading provider of medical oncology clinical information
systems and the premier source of US oncology data and analysis. Each month,
IntrinsiQ`s clinical software application, IntelliDose®, captures the treatment
decisions and details from more than 600 oncologists, for nearly 20,000 unique
patients, creating a database unrivaled in accuracy, detail and timeliness of
information about the medical oncology care process. IntelliDose ensures patient
safety though automation and standards designed to meet the needs of a specific
practice, saving staff time, maximizing reimbursement and reducing operating
costs. For more information, please visit www.intrinsiq.com.

IntrinsiQ Company Contact:
Diane Poth, 781-434-3304
diane.poth@intrinsiq.com
or
IntrinsiQ Media Contact:
George Robertson, 617-969-9192
grobertson@corporateink.com

Copyright Business Wire 2009

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.